Etodolac
Brand names: Etodolac, Etodolac Er
At a glance
- Medicare prescriptions, 2024
- 151,017
- Medicare drug cost
- $5.1M
- Average cost per prescription
- $33.87
- Clinicians who prescribed it
- 5,259
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Section INDICATIONS AND USAGE Carefully consider the potential benefits and risks of etodolac extended-release tablets and other treatment options before deciding to use etodolac extended-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Etodolac extended-release tablets are indicated: * For relief of signs and symptoms of juvenile arthritis * For relief of the signs and symptoms of rheumatoid arthritis * For relief of the signs and symptoms of osteoarthritis
From the FDA-approved prescribing information (label dated December 2024). Full labels on DailyMed (opens in a new tab)
Boxed warning
Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS and PRECAUTIONS). Etodolac extended-release tablets, 400 mg, 500 mg and 600 mg are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS). Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS).
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 22.2%
- Internal Medicine 12.9%
- Rheumatology 10.5%
- General Practice 9.9%
- Nurse Practitioners 8.3%
- Physician Assistants 6.6%
- Orthopedic Surgery 5.7%
- Pain Medicine 4.6%
- Periodontists 3.6%
- Dentists (general) 2.2%
- Physical Medicine & Rehabilitation (PM&R) 2.2%
- Sports Medicine 1.9%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 20% from 2019 to 2024.
Biggest change by state since 2019
- Oklahoma −11%
- Virginia −11%
- Texas −13%
- Indiana −13%
- Florida −14%
- Colorado (smallest change) −46%
- Louisiana (smallest change) −37%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 400 mg | brown oval tablet, 18 mm | I 49 |
Advanced Rx Pharmacy of Tennessee, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 600 mg | gray oval tablet, 20 mm | T600 |
Apotex Corp.
| Strength | Looks like | Imprint |
|---|---|---|
| 400 mg | white oval tablet, 19 mm | APO 041 400 |
| 500 mg | white oval tablet, 19 mm | APO 102 500 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 400 mg | white oval tablet, 19 mm | APO 041 400 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white oval tablet, 19 mm | APO 102 500 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.